Read our latest updates & insights

On 8 August 2024, Biocon Limited reported year on year consolidated revenue growth of 30% for Q2 2024, primarily as a result of a “one-time gain” from the strategic collaboration between Biocon and Eris Lifesciences announced in March 2024.  Although revenue for Biocon’s ge...

Fresenius Kabi has walked away from the Australian adalimumab market and cancelled its approvals for 40mg Idacio® pre-filled syringe and 40mg Idacio® pen products which were approved as biosimilars to AbbVie’s Humira®.  The withdrawals are listed on the TGA Medicines Shorta...

On 7 August 2024, Novo Nordisk released its financial report which showed a strong increase in profits in the first half of 2024.  Novo Nordisk’s total sales equalled DKK 133.4 billion in the first six months of 2024, an increase of 24% in DKK and 25% when measured ac...

Chugai announced that it has concluded a license agreement with Roche for Roche’s pipeline product RG6631, an anti-TL1A antibody, in late-stage product development for ulcerative colitis and Crohn’s disease.  Under the agreement, Chugai, which is 62% owned by Roche, obtains...

As reported in April this year, Celltrion presented the 78-week results of its Phase 3 study of CT-P41, biosimilar to Amgen’s Prolia® (denosumab), at the World Congress on Osteoporosis held in London from 11-14 April 2024.  On 6 August 2024, Celltrion announced that the res...

On 6 August 2024, Health New Zealand announced that it will now allow a small group of cancer patients to receive free early access to MSD’s Keytruda® (pembrolizumab) despite deciding earlier this week that it would not do so.

Pharmac is due to provide Keytruda® fund...

On 6 August 2024, Amgen announced its financial results for Q2/2024, reporting total revenues increased 20% to US$8.4 billion compared with Q2/2023.  Twelve of its products delivered at least double-digit sales growth in the quarter, including Prolia® (denosumab), Repatha® ...

On 6 August 2024, MSD announced that it has expanded its existing global development and commercialisation agreement with Daiichi Sankyo to include MK-6070, a T-cell engager targeting delta-like ligand 3 (DLL3).  Under the deal, the companies will jointly develop and commer...

On 5 August 2024, Lupin announced the successful completion of a global Phase III clinical study of LUBT010, its biosimilar to Genentech’s Lucentis® (ranibizumab).  The study showed that LUBT010 has comparable efficacy, safety and immunogenicity to Lucentis® in patients wit...